Результаты поиска - Diego Kauffmann‐Guerrero

  • Отображение 1 - 9 результаты of 9
Отмена результатов
  1. 1
    Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study

    Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study по Diego Kauffmann‐Guerrero, Kathrin Kahnert, Rosemarie Kiefl, Laura Sellmer, Julia Walter, Jürgen Behr, Amanda Tufman

    Опубликовано 2021
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  2. 2
    Guideline adherence of tumor board recommendations in lung cancer and transfer into clinical practice

    Guideline adherence of tumor board recommendations in lung cancer and transfer into clinical practice по Julia Walter, Caroline Moeller, Blerina Resuli, Diego Kauffmann‐Guerrero, Farkhad Manapov, Julien Dinkel, Jens Neumann, Julia Kovács, Christian Schneider, Rudolf M. Huber, Amanda Tufman

    Опубликовано 2023
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  3. 3
    Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy

    Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy по Jan Leipe, Lisa Christ, Andreas Arnoldi, Erik Mille, Frank Berger, Markus V. Heppt, Ilana Goldscheider, Diego Kauffmann‐Guerrero, Rudolf M. Huber, Claudia Dechant, Carola Berking, Hendrik Schulze‐Koops, Alla Skapenko

    Опубликовано 2018
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  4. 4
    Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

    Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program по Nikolaj Frost, Petros Christopoulos, Diego Kauffmann‐Guerrero, Jan A. Stratmann, Richard Riedel, Monica Schaefer, Jürgen Alt, S Gütz, Daniel C. Christoph, Eckart Laack, Martin Faehling, Richard Fischer, Klaus Fenchel, Sebastian P. Haen, Lukas C. Heukamp, Christian Schulz, Frank Griesinger

    Опубликовано 2021
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  5. 5
    Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality

    Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality по Kathrin Kahnert, Rudolf A. Jörres, Hans‐Ulrich Kauczor, Peter Alter, Franziska Trudzinski, Felix J.F. Herth, Bertram J. Jobst, Oliver Weinheimer, Sebastian Nauck, Pontus Mertsch, Diego Kauffmann‐Guerrero, Jürgen Behr, Robert Bals, Henrik Watz, Klaus F. Rabe, Tobias Welte, Claus Vogelmeier, Jürgen Biederer

    Опубликовано 2023
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  6. 6
    First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations

    First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations по Miriam Blasi, Jonas Kuon, H Lüders, Daniel Misch, Diego Kauffmann‐Guerrero, Moritz Hilbrandt, Daniel Kazdal, Roger-Fei Falkenstern-Ge, Björn Hackanson, Sebastian Dintner, Martin Faehling, Martina Kirchner, Anna‐Lena Volckmar, Hans‐Georg Kopp, Michael Allgäuer, Christian Grohé, Amanda Tufman, Martin Reck, Nikolaj Frost, Albrecht Stenzinger, Michael Thomas, Petros Christopoulos

    Опубликовано 2024
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations

    Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations по Felix Carl Saalfeld, Carina Wenzel, Petros Christopoulos, Sabine Merkelbach‐Bruse, Timm M. Reißig, Silke Laßmann, Steffen Thiel, Jan A. Stratmann, Ralf Marienfeld, Johannes Berger, Alexander Desuki, Janna-Lisa Velthaus, Diego Kauffmann‐Guerrero, Albrecht Stenzinger, Sebastian Michels, Thomas Herold, Michael Krämer, Sylvia Herold, Amanda Tufman, Sonja Loges, Jürgen Alt, Maria Joosten, Gerlinde Schmidtke-Schrezenmeier, Martin Sebastian, Susann Stephan-Falkenau, Cornelius F. Waller, Marcel Wiesweg, Jürgen Wolf, Michael Thomas, Daniela E. Aust, Martin Wermke

    Опубликовано 2021
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  8. 8
    Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)

    Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM) по Melanie Janning, Juliane Süptitz, Corinna Albers, Pierre Delpy, Amanda Tufman, J.-L. Velthaus-Rusik, Martin Reck, Andreas Jung, Diego Kauffmann‐Guerrero, Irina Bonzheim, Stephanie Brändlein, H-D. Hummel, Marcel Wiesweg, Hans‐Ulrich Schildhaus, Jan A. Stratmann, Martin Sebastian, J. Alt, J. Buth, Iréne Esposito, J. Berger, Lars Tögel, Felix Carl Saalfeld, Martin Wermke, Sabine Merkelbach‐Bruse, Axel M. Hillmer, Frederick Klauschen, Carsten Bokemeyer, Reinhard Buettner, Jennifer Moriatis Wolf, Sonja Loges, Ronald Simon, Guido Sauter, Alexander E. Volk, Jens Neumann, Frederick Klauschen, Wilko Weichert, Naser Kalhori, Reinhard Lüthen, Robert Stöhr, Chistoph Schubart, Heidemarie Wacker, Florian Fuchs, Nils Hartmann, Stefanie Graf, Christian Brandts, Peter J. Wild, Melanie Demes, Henning Reis, Gernot Rohde

    Опубликовано 2022
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  9. 9
    Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer

    Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Netwo... по Philip Bischoff, Martin Reck, Tobias R. Overbeck, Petros Christopoulos, Achim Rittmeyer, H Lüders, Jens Kollmeier, Jonas Kulhavy, Marcel Kemper, Niels Reinmuth, J Roper, Melanie Janning, Linna Sommer, Lukas Aguinarte, Myriam Koch, Marcel Wiesweg, Claas Wesseler, Cornelius F. Waller, Diego Kauffmann‐Guerrero, Albrecht Stenzinger, Susann Stephan-Falkenau, Marcel Trautmann, Silke Laßmann, Markus Tiemann, Frederick Klauschen, Martin Sebastian, Frank Griesinger, Jürgen Wolf, Sonja Loges, Nikolaj Frost, Moritz Hilbrandt, Juliane Süptitz, Christian Grah, Janna-Lisa Velthaus, Hans‐Georg Kopp, Bernd Schmidt, Susanne Horter, Stefanie Keymel, Enver Aydilek, Guergana Tritchkova, Matthias Raspe, Dražen Papić, Stefan Florian, David Horst, Peter J. Wild, Michael Thomas, Christian Grohé, Annalen Bleckmann, Martin Wermke, Horst-Dieter Hummel, Jan A. Stratmann, Wolfgang Schütte

    Опубликовано 2023
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: